buprenorphine depot (ALA-1000) / Alar Pharma - LARVOL DELTA

Design and investigation of novel iridoid-based peptide conjugates for targeting EGFR and its mutants L858R and T790M/L858R/C797S: an in silico study. (PubMed, Mol Divers) - "Interestingly, strong hydrophobic interactions were also observed with the C-terminal tail residues, such as PHE997 and ALA1000 as well as with ARG999 for the YSIPKSS peptide and most of the conjugates...Overall, our results show that the (7-DGA)2-K, di-conjugate, the (7-DGA)2-Y di-conjugate, and the neat YSIPKSS demonstrated strong and stable binding with the L858R mutant and the highly resistant triple mutant EGFR, respectively. The novel designed conjugates demonstrate potential for further optimization for laboratory studies aimed at developing new therapeutics for targeting specific EGFR mutant expressing cells."

Journal • Lung Cancer • Oncology • Solid Tumor • EGFR

Single Ascending Dose Study of ALA-1000 (clinicaltrials.gov) - P1; N=59; Completed; Sponsor: Alar Pharmaceuticals Inc.; Active, not recruiting ➔ Completed; Trial completion date: Dec 2021 ➔ May 2021; Trial primary completion date: Aug 2021 ➔ May 2021

Clinical • Trial completion • Trial completion date • Trial primary completion date • Addiction (Opioid and Alcohol) • Substance Abuse

Long-Acting Depot Buprenorphine For Drug Dependency Management (INHSU 2021) - No abstract available.

Single Ascending Dose Study of ALA-1000 (clinicaltrials.gov) - P1; N=59; Active, not recruiting; Sponsor: Alar Pharmaceuticals Inc.; Recruiting ➔ Active, not recruiting; Trial completion date: Dec 2020 ➔ Dec 2021; Trial primary completion date: Sep 2020 ➔ Aug 2021

Clinical • Enrollment closed • Trial completion date • Trial primary completion date • Addiction (Opioid and Alcohol)